SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2004
Savient Pharmaceuticals, Inc.
(Exact name of issuer as specified in its charter)
Delaware | | 0-15313 | | 13-3033811 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
|
One Tower Center, 14th Floor
East Brunswick, New Jersey | | 08816 |
(Address of Principal Executive Offices) | | (Zip Code) |
| | | | | | |
Registrant’s telephone number, including area code: (732) 418-9300
None.
(Former Name or Former Address, if Changed Since Last Report.)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On May 21, 2004, Savient Pharmaceuticals, Inc. (the “Company”) announced that Sim Fass, its Chairman Board and Chief Executive Officer would be retiring as Chairman of the Board and Chief Executive Officer of the Company effective upon the conclusion of the Company’s 2004 Annual Meeting of Stockholders. A copy of the press release issued by the Company with respect thereto is filed herewith as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
10.1 Agreement, dated May 21, 2004, between the Company and Sim Fass.
99.1 Press release issued by Savient Pharmaceuticals, Inc. on May 21, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| SAVIENT PHARMACEUTICALS, INC. |
| (Registrant) |
| | |
| | |
| By: | /s/ Christopher Clement | |
| | Christopher Clement |
| | President and Chief Operating Officer |
| | |
Dated: May 24, 2004 | | |
| | | | |
3
